General Information of Drug (ID: DMG4UJ6)

Drug Name
EVK-001 Drug Info
Indication
Disease Entry ICD 11 Status REF
Diabetic gastroparesis DA41.00 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DMG4UJ6

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug(s) Targeting Dopamine receptor (DR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Neupro DMHEAB1 Restless legs syndrome 7A80 Phase 4 [3]
ABBV-951 DMMWO7V Parkinson disease 8A00.0 Phase 3 [4]
ONC201 DMM5SCF Endometrial cancer 2C76 Phase 2 [5]
L-piperazino-3-phenyl-indane derivative 1 DM1STAD N. A. N. A. Patented [6]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine receptor (DR) TTWFZ1N NOUNIPROTAC Antagonist [2]

References

1 Clinical pipeline report, company report or official report of Evoke Pharma.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Rotigotine Transdermal Patch: A Review in Parkinson's Disease. CNS Drugs. 2019 Jul;33(7):707-718.
4 Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease. Ann Neurol. 2021 Jul;90(1):52-61.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.